Cystic Fibrosis Weekly Update

Contents:

CFF Aids Development of NO-based Therapy, BIOC51, for Resistant Bacteria, Vast Therapeutics Says
New Dual-antibiotic Powder Inhalation More Effective Against Drug-resistant Bacteria, Researchers Say

CFF Aids Development of NO-based Therapy, BIOC51, for Resistant Bacteria, Vast Therapeutics Says

Dec 19, 2018 07:00 am | Santiago Gisler

Vast Therapeutics announced that it received funding from the Cystic Fibrosis Foundation (CFF) to support further development of BIOC51, the company’s investigative treatment for antibiotic-resistant bacteria, including Pseudomonas aeruginosa, that is often the cause of lung infections in cystic fibrosis (CF) patients. P. aeruginosa infections set in when mucus accumulation clogs the airways, and the bacteria subsequently form […]
The post CFF Aids Development of NO-based Therapy, BIOC51, for Resistant Bacteria, Vast Therapeutics Says appeared first on Cystic Fibrosis News Today.

New Dual-antibiotic Powder Inhalation More Effective Against Drug-resistant Bacteria, Researchers Say

Dec 18, 2018 07:00 am | Alberto Molano

Purdue University researchers have invented a new way of delivering two antibiotics (colistin and ciprofloxacin) deep into the lungs of cystic fibrosis (CF) patients, enabling much more effective killing of antibiotic-resistant bacteria without exposing patients to high systemic doses of these therapies. “We are providing a promising option to fight the global crisis of antimicrobial resistance,” Qi […]
The post New Dual-antibiotic Powder Inhalation More Effective Against Drug-resistant Bacteria, Researchers Say appeared first on Cystic Fibrosis News Today.